BioData EU 2018 - Agenda Day 2

 

BioData EU- Day 2

08:55

Chair’s opening remarks

Stefan Platz
09:00

Transforming R&D productivity: How can we better turn science into medicine?

  • The future treatment for many of today’s diseases lies in discovering new biology to develop novel therapies. The advent of the genomics revolution brings with it an expanding list of pathways and targets to pursue – and with it, new drug discovery challenges
  • Validating drug targets by understanding and challenging scientific hypotheses has never been more important
  • Combining new technologies, focusing on medical understanding, challenging scientific hypotheses and driving strategic partnerships, we are making real progress in our ability to define and prosecute innovative treatment approaches for a variety of complex diseases
09:20

Sponsor keynote

10:00

Day One Initiative

Morning Refreshments

AI, AUTOMATION AND MACHINE LEARNING

ANALYTICS PLATFORMS AND DATA SETS

NEXT GEN SEQUENCING

DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS

ROCHE CURATED SESSION

Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
11:00

Chairs Opening Remarks

Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
11:00

Chairs Opening Remarks

Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
11:00

Chairs Opening Remarks

Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
11:00

Chairs Opening Remarks

Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
11:05

Using analytics tools to leverage data

Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
11:05

ROCHE CURATED SESSION

Track 5- AI, AUTOMATION AND MACHINE LEARNING
11:25

Predicting clinical trial success with Artificial Intelligence

Armin Schneider, VP Scientific and Medical Affairs, Molecular Health
Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
11:25

IQVIA

Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
11:25

GENALICE

Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
11:25

CYTEL

Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
11:25

Sponsor Available

Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
11:45

Machine Learning meets the Human Genome

Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
11:45

A comprehensive analysis of a RNA-seq dataset at the gene-, isoform- and exon-levels to discover disease progressive biomarkers during diabetic nephropathy

  • Introduction to ZSF1, a preclinical model for type 2 diabetic nephropathy
  • Why RNA-seq data should be additionally analyzed at the isoform and exon levels
Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
11:45

Use case: Federated EHR research technology to support clinical trial protocol optimisation: Evidence from EHR4CR and the InSite platform

  • The new federated EHR technology approach – the case of EHR4CR project and deployment program inEurope
  • Utilise a combination of data sources to effectively structure your developmental strategy
  • Outlook on performing Pragmatic Clinical Trials & Conclusions
Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
11:45

ROCHE CURATED SESSION

round tables
12:05

Round Tables

Round Table D: Analytics for Regulatory and Safety RWE and Epidemiology
Andrew Bate

Andrew Bate, Senior Director, Analytics Team Lead, Epidemiology, Pfizer

Round Table E: Digital Endopoints and Validation
Ieuan Clay

Ieuan Clay, Group Lead Digital Endpoints, Novartis

Round Table F: AI in Ageing Research and Longevity
Kristen Fortney

Kristen Fortney, Chief Executive Officer, Bioage Labs

Round Table G: ONTOFORCE
Round Table I: Human Protein Atlas: Big data for human biology and precision medicine
Cecilia Lindskog

Cecilia Lindskog, Director Tissue Atlas, Human Protein Atlas, Uppsala University

Round Table J: Databiology
Round Table K: Digital Substudies- Big Data in Drug Discovery
Lena Granovsky

Lena Granovsky, Director, Analytics and Big Data, Teva Pharmaceuticals

Round Table L: Applied Health Science Research to Improve Clinical Outcomes
Daniel Zahnd

Daniel Zahnd, Head of Digital Health, Bern University of Applied Science

Round Table P: Developing data sharing across the Wellcome Trust
Nicola Perrin

Nicola Perrin, Head, Data for Science and Health priority, Wellcome Trust

Round Table Q: Using AI in Drug Development
Edward Painter

Edward Painter, Founder & CEI, A2A Pharmaceuticsls

Round Table R: Computing at the Exascale – Developing large scale genomics and heath record architecture
Jeremy Cohen

Jeremy Cohen, Senior Program Manager, Oak Ridge National Laboratory

Round Table T: Securing budget for organising data so its findable and usable
Vibhor Gupta

Vibhor Gupta, Entrepreneur In Residence, Pangaea

Round Table V: Everything you need to know about the Spliceosome
Round Table W: Digital Healthcare: When is healthcare going to be digitalised
Jasmin Saric

Jasmin Saric, Head of Digital Ideation and Scouting, BI X GmbH

Round Table X: Challenges in Data Curation and Quality
Ramin Daron

Ramin Daron, VP, Data Architecture and Technology, Takeda Pharmaceuticals

Networking Lunch

AI, AUTOMATION AND MACHINE LEARNING

ANALYTICS PLATFORMS AND DATA SETS

NEXT GEN SEQUENCING

DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS

PRECISION MEDICINE

Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
14:05

Chairs Opening Remarks

Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
14:05

Chairs Opening Remarks

Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
14:05

Chairs Opening Remarks

Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
14:10

Applied Technology and Innovation

Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
14:10

Different whole genome sequencing strategies to study HPVs role in cancer development.

  • How HPV is involved in the development of different cancers
  • Strengths and weaknesses of different whole genome sequencing strategies to study HPV integrations in cancer
  • Time vs Money where should you invest?
Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
14:10

Application of ML to lupus nephritis and extrarenal lupus clinical dataset - lesson learned and main takeaways

  • We adapted Eureqa software (Nutonian) to screen baseline and time-varying clinical and laboratory parameters for associations with outcome using pooled data from recent trials in lupus nephritis (LN) and extrarenal lupus (ERL)
  • In LN, Eureqa confirmed known associations with outcome but also several trivial associations. Eureqa did not identify meaningful associations between clinical variables and outcome in ERL trials
  • Eureqa is a potentially exciting tool to assist with discovery of novel associations in clinical data and hypothesis generation
Track 5- AI, AUTOMATION AND MACHINE LEARNING
14:30

Copyright Clearance Center

Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
14:30

CLOUDIAN

Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
14:30

Using AI for drug target discovery

  • Case studies over the last five years
  • Precision Medicine based clinical trials
  • RWE in practice
Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
14:30

PRECISION FOR MEDICINE

Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
14:30

COPYRIGHT CLEARANCE CENTER

Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
14:50

Omics and pathway analysis for disease understanding in pain

  • Pain as a disease
  • Interpretation of Omics data and Pathways
  • Pain Landscapes and Disease Understanding
Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
14:50

Precision and recall oncology: combining multiple gene alterations for improved identification of drug-sensitive tumours

  • A small proportion of tumours present strong gene-drug response associations that can be used as predictive biomarkers of drug response.
  • Combining multiple gene alterations of the tumours via Machine Learning (ML) often results in better discrimination than that provided by the corresponding single-gene marker.
  • ML multi-gene predictors generally retrieve a much higher proportion of treatment-sensitive tumours (i.e. they have a higher recall). This suggests that substantially more patients could eventually benefit from effective drug selection by applying this ML methodology to existing clinical pharmacogenomics data sets

AI, AUTOMATION AND MACHINE LEARNING

SOFTWARE & APPLICATIONS

EVIDENCE

DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS

PRECISION MEDICINE

Track 5- AI, AUTOMATION AND MACHINE LEARNING
15:40

Federated learning: leveraging the power of private data

  • Federated learning approach allows to build powerfull models from separated datasets
  • This techniques enables to build efficients models without compromising the privacy of individual datasets
  • Examples of applications in medicine
Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
15:40

The Genomics of Rare Diseases at Boston Children’s Hospital

  • The importance of phenotyping, transparency, and patient engagement
  • The delicate balance of data sharing, discovery, and translation to the clinic
  • Case studies of big data projects at a tertiary children’s hospital
  • Collaborations with Industry to make rare disease discoveries
Track 5- AI, AUTOMATION AND MACHINE LEARNING
16:00

NURITAS

Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
16:00

SAP

Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
16:00

Sponsor Available

Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
16:00

Sponsor Available

Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
16:00

Sponsor Available

Track 5- AI, AUTOMATION AND MACHINE LEARNING
16:20

From data lakes to actionable data

  • We can now build large collection of data spanning proprietary and public datasets (e.g.: -omics, RWE)
  • Leveraging these resources requires a data checking, cleansing and preparation process. This is an expensive process, that often needs to repeat for different investigations.
  • To which extent can we automate or semi-automate data curation processes?
  • We report on experiences and ideas in the use of rules, machine learning and AI systems to automate data curation process.
  • We discuss limitations, value and perspective developments.
Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
16:20

How to Infuse the Human Perspective to Digital Health?"

  • Most paradigms of the digital health revolution, such as digital therapeutics, precision medicine, outcome-based health systems, and self-care are critically dependent on changing behavioural aspects of patients
  • Impactful digital health initiatives are therefore best co-developed with patients in a human-centric manner
  • Patients can participate in product and service development at scale through a novel service platform for patient engagement, specifically trained resources, and a network of relevant partners
Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
16:20

Putting data to work in drug discovery - building an AI-enhanced future

Data, information and knowledge management is a critical foundation for building an AI-enhanced future for drug discovery. I will show examples of our work, and in particular discuss how technology interfaces with culture in this area”
Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
16:20

Scaling up trustworthy data access for personalised care and research

  • Real World Evidence decision making and Precision Medicine need greater access to big health data: clinical data, genomic biomarkers, wellness and lifestyle.
  • Trustworthy data sharing is vital to scaling up data access: trust in privacy protection, trust in the quality of the data and trust in how data are used.
  • Stakeholders and efforts need to collaborate, especially with patients, to develop a portfolio of equitable and acceptable models that can be promoted globally.

End of Conference

last published: 18/Sep/18 12:55 GMT

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Alistair Wilmot
+44 (0)207 092 1174

alistair.wilmot@terrapinn.com


To speak:
Chris Shanks
+44 (0)207 092 1151

chris.shanks@terrapinn.com